The reversible and JAKi sensitive nature of the CDC42hiCD14+ cells predicts that RA patients carrying the CDC42-related MetSig may favor of early use of this targeted intervention, which justifies its evaluation prior to treatment choice. Here, CDC42 is linked to rheumatoid arthritis.